Compare AXR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXR | AGEN |
|---|---|---|
| Founded | 1961 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.3M | 126.2M |
| IPO Year | N/A | 2000 |
| Metric | AXR | AGEN |
|---|---|---|
| Price | $21.74 | $3.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 5.2K | ★ 983.6K |
| Earning Date | 03-06-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | $45,947,000.00 | ★ $106,829,000.00 |
| Revenue This Year | $12.43 | $23.68 |
| Revenue Next Year | $4.48 | $23.17 |
| P/E Ratio | $11.22 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.60 | $1.38 |
| 52 Week High | $34.00 | $7.34 |
| Indicator | AXR | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 66.97 | 41.53 |
| Support Level | $21.27 | $3.01 |
| Resistance Level | $21.74 | $4.87 |
| Average True Range (ATR) | 0.51 | 0.36 |
| MACD | 0.38 | 0.05 |
| Stochastic Oscillator | 100.00 | 15.95 |
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).